Section Arrow
NGNE.NASDAQ
- Neurogene
Quotes are at least 15-min delayed:2025/09/13 22:59 EDT
Regular Hours
Last
 19
-1.08 (-5.38%)
Day High 
20.42 
Prev. Close
20.08 
1-M High
21.59 
Volume 
123.07K 
Bid
18.85
Ask
19.7
Day Low
18.765 
Open
20.07 
1-M Low
18 
Market Cap 
286.58M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 19.38 
20-SMA 19.68 
50-SMA 20.75 
52-W High 74.49 
52-W Low 6.875 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.31/-4.98
Enterprise Value
296.73M
Balance Sheet
Book Value Per Share
19.15
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
925.00K
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
COCPCocrystal Pharma1.58+0.14+9.72%-- 
ADAPAdaptimmune Therapeutics plc0.056+0.0055+10.89%-- 
PLRZPolyrizon Ltd1.2+0.2225+22.76%-- 
MRNAModerna23.51-1.88-7.40%-- 
HCWBHCW Biologics Inc5.59+2.27+68.37%-- 
Quotes are at least 15-min delayed:2025/09/13 22:59 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.